Table 2.
Type of IBD | Study design | RR (95% CI) | Heterogeneity | Number of studies | Number of participants | Subgroup differences | Residual heterogeneity |
---|---|---|---|---|---|---|---|
Crohn’s disease | Case-control | 1.25 (1.05–1.50) | I2 = 89% | 11 | 513,008 | p = 0.24 REF |
I2 = 69% R2 = 0% p < 0.0001 |
Cohort | 1.45 (1.23–1.71) | I2 = 82% | 4 | 311,165 | β 1.6 (95% CI−0.14 to 0.46) | ||
Ulcerative colitis | Case-control | 1.33 (1.24–1.42) | I2 = 89% | 12 | 512,807 | p = 0.78 REF |
I2 = 91% R2 = 22% p < 0.0001 |
Cohort | 1.40 (0.99–1.98) | I2 = 94% | 4 | 306,907 | β −0.046 (95% CI −0.21 to 0.12) |